Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.

Slides:

Advertisements

Similar presentations

Acquisition of tumour multidrug resistance inevitable in most advanced solid tumours – Failing to cure the majority of advanced solid tumours – Declining.

Advertisements

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

PhyloSub Jiao et. al. BMC Bioinformatics 2014, 15:35.

Habil Zare Department of Genome Sciences University of Washington

Genetics-multistep tumorigenesis genomic integrity & cancer Sections from Weinberg’s ‘the biology of Cancer’ Cancer genetics and genomics Selected.

We obtained breast cancer tissues from the Breast Cancer Biospecimen Repository of Fred Hutchinson Cancer Research Center. We performed two rounds of next-gen.

Samuel Aparicio, B.M., B.Ch., Ph.D., and Carlos Caldas, M.D.

Tumor Heterogeneity: From biological concepts to computational methods Bo Li, PhD Dana Farber Cancer Institute Harvard Statistics Department.

Natural History, Response to Treatment

The NEW ENGLNAD JOURNAL of MEDICINE 368;18 MARCH 28, 2013

by David Grimwade, Adam Ivey, and Brian J. P. Huntly

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Nicholas McGranahan, Charles Swanton Cell

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Impact of efficient and inefficient therapies on CTCs and ctDNA.

Volume 67, Issue 4, Pages (April 2015)

Genomic alterations in breast cancer cell line MDA-MB-231.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Figure 1 The dynamic nature of resistance mechanisms can be

Copy-number alterations in an archival breast cancer sample.

Potential clinical actionability.

Volume 172, Issue 1, Pages (January 2018)

Circulating tumor DNA: Solid data from liquid biopsies

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Figure 3 Tumours secrete factors that cause systemic immunosuppression

TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,

New Insights on Treatment Strategies for mCRC:

Inferring Tumor Phylogenies from Multi-region Sequencing

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Nicholas McGranahan, Charles Swanton Cancer Cell

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Frequent alterations identified and potential actionability.

Normalizing the tumor microenvironment

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

EGFR and cetuximab sensitivity of SCCUAT

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.

Biomechanical force may promote tumor progression by establishing an aggressive tumor cell hierarchy. Biomechanical force may promote tumor progression.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Duration of treatment and intervals of radiographic and ctDNA response

Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer.

Increased levels of acetylated histone H3 are observed in normal PBMCs and circulating tumor cells obtained from patients post-depsipeptide treatment.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Heterogeneity origins and maintenance.

Delineating cancer evolution with single-cell sequencing

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Combined inhibition of coamplified RTKs is required for response.

Possible outcomes of therapeutic treatments using the spiral model.

Ten most frequent TCRs in the bulk 12TILs comprise >99% of the TIL population, and the neoantigens are shown to be the most dominant clones. Ten most frequent.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Strategies for personalized precision immunotherapy.

Enrichment of two rare SNPs among ABC DLBCL tumors.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Integrated analysis of gene expression and copy number alterations.

Immunological effects of anticancer therapy.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Presentation transcript:

Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Tumors are molecularly heterogeneous. Multiregion biopsies provide a snapshot of this heterogeneity, allowing the reconstruction of a tumor phylogenetic tree and the identification of ubiquitous, shared, or private alterations. Liquid biopsy allows, through ctDNA analysis, real-time monitoring of changes in tumor heterogeneity under the selective pressure of anticancer treatments. Analysis of the allelic frequencies of subclonal alterations provides a measure of growth dynamics of the different cell populations within a tumor, whereas quantification of trunk alterations allows normalization for tumor burden. Circulating tumor cells could integrate biological information obtained by ctDNA sequencing, and circulating immune cells could help describe the evolution of the tumor-responsive immune microenvironment. Nabil Amirouchene-Angelozzi et al. Cancer Discov 2017;7:805-817 ©2017 by American Association for Cancer Research